Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07639086 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07639086 is a Phase 2 study that has not yet begun recruiting, run by Virginia Commonwealth University. The registered enrollment target is 20 participants.
The verdict
NCT07639086, a Phase 2 study, has not yet begun recruiting, sponsored by Virginia Commonwealth University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
Interventions
- DRUG Sacituzumab Tirumotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2032-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07639086
The ClinicalTrials.gov registry entry for NCT07639086 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sacituzumab Tirumotecan is the first listed.
NCT07639086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07639086 about?
NCT07639086 is a clinical study titled "Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy". This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
What is the current status of trial NCT07639086?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-08-31. Estimated completion is 2032-03-31.
What interventions are being tested in trial NCT07639086?
The interventions under investigation include: Sacituzumab Tirumotecan (DRUG).
Who is sponsoring clinical trial NCT07639086?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.